Glycorex Transplantation Valuation

Is GTAB B undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of GTAB B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate GTAB B's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate GTAB B's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for GTAB B?

Key metric: As GTAB B is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for GTAB B. This is calculated by dividing GTAB B's market cap by their current revenue.
What is GTAB B's PS Ratio?
PS Ratio	4.3x
Sales	SEK 31.22m
Market Cap	SEK 144.02m

GTAB B key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	4.7x
Enterprise Value/EBITDA	-9.9x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does GTAB B's PS Ratio compare to its peers?

The above table shows the PS ratio for GTAB B vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	8.7x
SDOS ScandiDos	1.5x	n/a	SEK 93.5m
EPIS B Episurf Medical	7.9x	93.5%	SEK 98.2m
NOSA Nosa Plugs	8.4x	38.5%	SEK 125.1m
NEOLA Neola Medical	17.3x	39.8%	SEK 190.8m
GTAB B Glycorex Transplantation	4.3x	n/a	SEK 144.0m

Price-To-Sales vs Peers: GTAB B is good value based on its Price-To-Sales Ratio (4.3x) compared to the peer average (8.7x).

Price to Sales Ratio vs Industry

How does GTAB B's PS Ratio compare vs other companies in the SE Medical Equipment Industry?

12 Companies	Price / Sales	Estimated Growth	Market Cap
ARJO B Arjo	0.8x	3.6%	US$808.67m
CARE Careium	0.8x	10.2%	US$62.46m
BOUL Boule Diagnostics	0.5x	5.6%	US$23.73m
ARCOMA Arcoma	0.8x	8.3%	US$13.05m

12 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: GTAB B is good value based on its Price-To-Sales Ratio (4.3x) compared to the Swedish Medical Equipment industry average (4.7x).

Price to Sales Ratio vs Fair Ratio

What is GTAB B's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GTAB B PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	4.3x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate GTAB B's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Iconovo

SEK 79.9m

Develops and licenses inhalation medications in Sweden.

ICO

SEK 5.02

-1.6%

-46.3%

Arcoma

SEK 144.4m

Develops, produces, and provides radiology solutions worldwide.

ARCOMA

SEK 10.95

1.4%

47.0%

Dignitana

SEK 96.7m

A medical technology company, engages in the development, production, and marketing of medical cooling devices in the United States and internationally.

DIGN

SEK 1.20

4.3%

-45.5%